H

Active Director Director DIN 09650083
DIN 09650083 First appointment Jun 2022 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2022
Shareholding value •••• Premium profile

About Hridya

Data last updated:

Hridya is a Director at Veta Genomics Private Limited (since 2022). The company operates in Healthcare. Veta Genomics Private Limited reported revenue of ₹43.4 Lakh (FY 2024).

DIN 09650083
Primary Designation Director
Industry Healthcare
First Appointment 23 Jun 2022
Oldest Company Age 4 yrs
Largest company Veta Genomics Private Limited · ₹43.4 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Veta Genomics Private Limited U85100KL2022PTC076344
Director23 Jun 20222022₹43.4 Lakh (FY 2024)Active

Board colleagues of Hridya

Directorship timeline

Open interactive timeline →
Veta Genomics Private Limited
Premium access

Shareholding and investment profile for Hridya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hridya

Hridya currently holds 1 directorship: Veta Genomics Private Limited (Director, since 23 Jun 2022, revenue ₹43.4 Lakh (FY 2024)).

Hridya was first appointed on 23 Jun 2022 as Director at Veta Genomics Private Limited.

The current boards of Hridya's companies include Manoj Kumar (Veta Genomics Private Limited), Neduveliparambil Murugan Praveen (Veta Genomics Private Limited), Shaju Thuppinikkattu Kunjalan (Veta Genomics Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available